StreetInsider.com News Articles

Repligen (RGEN) PT Raised to $210 at HSBC

Tue, 01 Sep 2026 02:16:54 -0400

HSBC analyst Shubhangi Gupta raised the price target on Repligen (NASDAQ: RGEN) to $210.00 (from $170.00) while maintaining a Buy rating.

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 07:30:00 -0400

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 07:30:00 -0400

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 07:30:00 -0400

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 07:30:00 -0400

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period

Form S-4 REPLIGEN CORP

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970319.html

Form S-4 REPLIGEN CORP

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970319.html

Form 4 REPLIGEN CORP For: Aug 20 Filed by: Loeillot Olivier

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961416.html

Form 4 REPLIGEN CORP For: Aug 20 Filed by: Loeillot Olivier

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961416.html

Form 144 REPLIGEN CORP Filed by: Loeillot Olivier

Thu, 20 Aug 2026 11:54:00 -0400

si-local-file:///var/storage/secattach/20260820/26954963.html

Form 144 REPLIGEN CORP Filed by: Loeillot Olivier

Thu, 20 Aug 2026 11:54:00 -0400

si-local-file:///var/storage/secattach/20260820/26954963.html

Repligen (RGEN) call put ratio 5.6 calls to 1 put

Wed, 19 Aug 2026 11:23:33 -0400

Repligen (NASDAQ: RGEN) 30-day call option implied volatility is 43; compared to its 52-week range of 38 to 93. Call put ratio 5.6 calls to 1 put.

Repligen (RGEN) call put ratio 1 call to 6.7 puts into share price up before the bell

Wed, 19 Aug 2026 09:12:51 -0400

Repligen (NASDAQ: RGEN) 30-day call option implied volatility is 43; compared to its 52-week range of 38 to 93. Call put ratio 1 call to 6.7 puts.

Form SCHEDULE 13G/A REPLIGEN CORP Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926602.html

Form SCHEDULE 13G/A REPLIGEN CORP Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926602.html

Form SCHEDULE 13G REPLIGEN CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:46:00 -0400

si-local-file:///var/storage/secattach/20260731/26848436.html

Form SCHEDULE 13G REPLIGEN CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:46:00 -0400

si-local-file:///var/storage/secattach/20260731/26848436.html

Repligen (RGEN) PT Raised to $185 at Wells Fargo

Thu, 30 Jul 2026 08:35:29 -0400

Wells Fargo analyst Evan Stampler raised the price target on Repligen (NASDAQ: RGEN) to $185.00 (from $180.00) while maintaining a Overweight rating.

Form 10-Q REPLIGEN CORP For: Jun 30

Wed, 29 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260729/26835457.html

Form 10-Q REPLIGEN CORP For: Jun 30

Wed, 29 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260729/26835457.html

Repligen (RGEN) PT Raised to $175 at JPMorgan

Wed, 29 Jul 2026 08:55:33 -0400

JPMorgan analyst Casey Woodring raised the price target on Repligen (NASDAQ: RGEN) to $175.00 (from $165.00) while maintaining a Overweight rating.

Canaccord Reiterates Hold Rating on Repligen (RGEN)

Wed, 29 Jul 2026 06:47:50 -0400

Canaccord analyst Kyle Mikson reiterated a Hold rating and $145.00 price target on Repligen (NASDAQ: RGEN).

The analyst commented: "We reiterate our HOLD rating on Repligen (RGEN) shares and maintain our price target at $145. Before the market open on Tuesday, July 28, the company reported 2Q26 results that were essentially in line with our estimates and preliminary results announced on 7/22. RGEN achieved revenue growth across all franchises (led by Proteins and Process Analytics). China revenue increased 60% y/y and consumables revenue expanded high-teens. Although capital equipment revenue was more muted (increasing high-single-digits in 1H26), sequential orders increased significantly. We

Repligen (RGEN) PT Raised to $185 at RBC Capital

Wed, 29 Jul 2026 06:21:38 -0400

RBC Capital analyst Dan Leonard raised the price target on Repligen (NASDAQ: RGEN) to $185.00 (from $160.00) while maintaining a Outperform rating.

Repligen (RGEN) PT Raised to $160 at Wolfe Research

Wed, 29 Jul 2026 05:35:05 -0400

Wolfe Research analyst Mike Polark raised the price target on Repligen (NASDAQ: RGEN) to $160.00 (from $145.00) while maintaining a Outperform rating.

Repligen (RGEN) PT Raised to $160 at Jefferies

Tue, 28 Jul 2026 13:21:31 -0400

Jefferies analyst Matthew Stanton raised the price target on Repligen (NASDAQ: RGEN) to $160.00 (from $142.00) while maintaining a Hold rating.